| Literature DB >> 29655806 |
Marco Marietta1, Elisa Romagnoli2, Benilde Cosmi3, Valeria Coluccio4, Mario Luppi5.
Abstract
Despite recent advances in the treatment of Deep Vein Thrombosis (DVT) provided by Direct Oral Anticoagulants (DOAC), a substantial proportion of lower limb DVT patients will develop some degree of post-thrombotic syndrome (PTS) within 2 years. Systemic thrombolysis, although effective in reducing the risk of PTS and leg ulceration, is associated with a high risk of major bleeding, making it unsuitable for the vast majority of patients. A local approach, aimed at delivering the fibrinolytic drug directly into, or near to, the thrombus surface, is attractive because of the possibility of lowering of the administered drug dose, thus reducing the bleeding risks. However, even after the recent publication of the ATTRACT trial, only weak evidence is available about the efficacy and safety of Catheter Directed Thrombolysis (CDT), either alone (pharmacological technique) or in combination with additional endovascular approaches (pharmacomechanical technique, PMT) including percutaneous mechanical thrombectomy, angioplasty with or without stenting and ultrasound-assisted CDT. The present review is aimed at providing the physicians with a comprehensive evaluation of the current evidence about this relevant topic, in order to build a reliable conceptual framework for a more appropriate use of this resource.Entities:
Keywords: Anticoagulant drugs; Apixaban; Dabigatran; Deep Vein Thrombosis; Edoxaban; Mechanical thrombolysis; Rivaroxaban; Thrombolytic therapy; Warfarin
Mesh:
Substances:
Year: 2018 PMID: 29655806 DOI: 10.1016/j.ejim.2018.04.003
Source DB: PubMed Journal: Eur J Intern Med ISSN: 0953-6205 Impact factor: 4.487